AR062116A1 - USEFUL CONDENSED TRICICLIC HETEROCICLES TO TREAT CNS DISORDERS - Google Patents

USEFUL CONDENSED TRICICLIC HETEROCICLES TO TREAT CNS DISORDERS

Info

Publication number
AR062116A1
AR062116A1 ARP070103324A ARP070103324A AR062116A1 AR 062116 A1 AR062116 A1 AR 062116A1 AR P070103324 A ARP070103324 A AR P070103324A AR P070103324 A ARP070103324 A AR P070103324A AR 062116 A1 AR062116 A1 AR 062116A1
Authority
AR
Argentina
Prior art keywords
alkyl
triciclic
heterocicles
cns disorders
alkanediyl
Prior art date
Application number
ARP070103324A
Other languages
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR062116A1 publication Critical patent/AR062116A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Uso de los compuestos de la formula 1 para tratar trastornos del sistema nervioso central, que incluyen esquizofrenia y otros trastornos sicoticos. Reivindicacion 1: Un compuesto de la formula 1, o una sal farmacéuticamente aceptable del mismo, en la que L se selecciona de entre un enlace y alcanodiilo C1-6; Z1 se selecciona de entre un enlace y alcanodiilo C1-2; Z2 se selecciona de entre alcanodiilo C1-2; R1, R2, R3, R4, R5, R6, R7, R8 y R9 se seleccionan cada uno independientemente de entre H, halogeno, ciano, alquilo C1-6, haloalquilo C1-6 y carbamoílo; y R10 se selecciona de entre H, alquilo C1-6, haloalquilo C1-6, alcanoilo C1-7, carbamoílo, alquil C1-6-aminocarbonilo, alquil C1-6sulfonilo, alquil C1-6-sulfonilalquilo C1-2, alquil C1-6aminosulfonilo y alquil C1-6aminosulfonilalquilo C1-2.Use of the compounds of formula 1 to treat disorders of the central nervous system, which include schizophrenia and other psychotic disorders. Claim 1: A compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein L is selected from a bond and C1-6 alkanediyl; Z1 is selected from a bond and C1-2 alkanediyl; Z2 is selected from C1-2 alkanediyl; R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each independently selected from H, halogen, cyano, C1-6 alkyl, C1-6 haloalkyl and carbamoyl; and R 10 is selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 1-7 alkanoyl, carbamoyl, C 1-6 alkylcarbonyl, C 1-6 alkyl sulfonyl, C 1-6 alkyl sulfonylalkyl, C 1-6 alkyl 6-amino sulfonyl and C 1-6 alkyl amino sulfonylalkyl-C 1-2 alkyl.

ARP070103324A 2006-07-28 2007-07-26 USEFUL CONDENSED TRICICLIC HETEROCICLES TO TREAT CNS DISORDERS AR062116A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82064206P 2006-07-28 2006-07-28

Publications (1)

Publication Number Publication Date
AR062116A1 true AR062116A1 (en) 2008-10-15

Family

ID=38658573

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103324A AR062116A1 (en) 2006-07-28 2007-07-26 USEFUL CONDENSED TRICICLIC HETEROCICLES TO TREAT CNS DISORDERS

Country Status (2)

Country Link
AR (1) AR062116A1 (en)
WO (1) WO2008015516A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN106608875A (en) * 2015-10-26 2017-05-03 江苏恩华药业股份有限公司 Synthesis and application of fused heterocycle derivative
CN112142737B (en) * 2019-06-29 2022-03-18 武汉珈瑜科技有限公司 Solid form of hydrochloride of medicine for treating schizophrenia
CN114728956B (en) * 2019-11-18 2024-01-12 上海枢境生物科技有限公司 Fused heterocyclic derivative and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000863A1 (en) * 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
ZA9711376B (en) * 1996-12-20 1998-07-21 Lundbeck & Co As H Indole or dihydroindole derivatives
DE10217006A1 (en) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituted indoles
BR0314393A (en) * 2002-09-17 2005-07-19 Warner Lambert Co Heterocyclic Substituted Piperazines for the Treatment of Schizophrenia

Also Published As

Publication number Publication date
WO2008015516A1 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
PE20061298A1 (en) DIHYDROBENZOFURAN-DERIVED COMPOUNDS AS AGONISTS OF THE SEROTONIN 5-HT2C RECEPTOR
AR038341A1 (en) COMPOUNDS THAT ARE ALFA-1 RECEIVER AGONISTS PREFERRED ALFA-1A / L RECEIVER AGONISTS
AR065280A1 (en) ANTIPARASITARY AGENTS
ECSP066520A (en) DERIVATIVES OF DIHYDROBENZOFURANYL ALCANAMINE AND METHODS FOR USE
WO2007022934A3 (en) Azabicyclo (3, 1, 0) hexan derivatives useful as modulators of dopamine d3 receptors
AR056560A1 (en) PIRROLOPIRIDINONES AS MODULATORS CB1
PE20020720A1 (en) BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LINKS FOR GABAA RECEPTORS
NO20071476L (en) Antidiuretic agents.
AR073348A1 (en) CYCLE INHIBITORS OF 11 BETA-HYDROXIESTEROID DEHYDROGENASE 1
PE20020721A1 (en) QUINUCLIDINE DERIVATIVES AS ANTIMUSCARINAL AGENTS M3
AR049388A1 (en) HETEROCICLES AS INHIBITORS OF ALDOSTERONA SINTASA
PE20141010A1 (en) PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICINES FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED DISEASES, AND INFLAMMATORY DISEASES
AR035532A1 (en) DIAMINOTIAZOLES, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM, INTERMEDIARIES FOR THE PREPARATION OF SUCH COMPOUNDS, USE OF SUCH COMPOUNDS IN THE PREPARATION OF MEDICINES, AND PROCESSES FOR THE PREPARATION OF SUCH COMPOUNDS
AR053739A1 (en) ESPIRO COMPOUNDS CONDENSED AS INHIBITORS OF ALDOSTERONA SINTASA
AR056886A1 (en) PIRROLOPIRIDINE COMPOUNDS REPLACED INHIBITORS OF KINASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES IN THE TREATMENT OF CANCER
AR052866A1 (en) SUBSTITUTED MONOCICLIC PHENYL-METANONES
AR060840A1 (en) VR1 BENCIMIDAZOLIC MODULATORS
MX2007005199A (en) Substituted indolizines and derivatives as cns agents.
AR054083A1 (en) IMIDAZOL COMPOUNDS AND ITS USE TO PREPARE MEDICATIONS
AR061369A1 (en) PIRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
AR040278A1 (en) GLUCOCORTICOID RECEIVER LINKS FOR THE TREATMENT OF METABOLIC DISORDERS
ATE420859T1 (en) AZABICYCLOÄ3.1.0ÜHEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS
AR047958A1 (en) DERIVATIVES OF 1-BENCIL-5-PIPERAZIN-1-IL-3,4 DIHIDRO-1H-QUINAZOLIN-2-ONA AND ITS DERIVATIVES 1H-BENZO (1,2,6) TIADIAZINA-2,2-DIOXIDES AND 1,4 -DIHIDRO-BENZO (D) (1,3) OXAZINAS-2-ONA, AS MODULATORS OF THE 5-HT RECEIVER, FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM.
AR042002A1 (en) SUBSTITUTED BENZOXAZINONAS, OBTAINING PROCESS AND USES FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES.
AR062116A1 (en) USEFUL CONDENSED TRICICLIC HETEROCICLES TO TREAT CNS DISORDERS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal